Revelation Biosciences (NASDAQ: REVB), a clinical-stage life sciences company focused on the development of immunologic based therapies for the prevention and treatment of disease, announced its entry into a definitive agreement with a leading health care-focused institutional investor. Under the agreement, the company agreed to sell 1,293,126 shares of common stock, each at a gross purchase price of $3.00. Revelation additionally agreed to issue to the investor unregistered warrants to purchase up to 2,586,667 shares (the “common warrants”), as well as unregistered pre-funded warrants to purchase up to 1,293,541 shares (the “pre-funded warrants” and together with the common warrants, the “warrants”) in a concurrent private placement. The common warrants, with an exercise price of $3.29 per share, will become exercisable in six months after their date of issuance and will expire five and a half years from their date of issuance. The pre-funded warrants have been funded to the amount of $3.00 with $0.0001 payable on exercise. Roth Capital Partners acted as sole placement agent for the offering, which closed on Jan. 25, 2022.
To view the full press release, visit https://nnw.fm/B3AgD
About Revelation Biosciences Inc.
Revelation Biosciences is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has several product candidates in development. REVTx-99a, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99b is being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. In addition to Revelation’s therapeutic pipeline, Revelation is also developing REVDx-501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation. For more information, please visit www.RevBiosciences.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork